Rilpivirine(rill pah vye’ rin)
Edurant
PREGNANCY CATEGORY B
Drug Classes
Antiviral
Nonnucleoside reverse transcriptase inhibitor
Therapeutic Actions
Binds directly to reverse transcriptase and blocks both RNA- and DNA-dependent polymerase activity, leading to inability for viral replication, a decrease in viral load, and subsequent increase; increases number of healthy CD4 cells, does not inhibit DNA polymerase.
Indications
Treatment of HIV infection in treatment-naïve adults, in combination with at least two other antiretrovirals
Contraindications and Cautions
Contraindicated with history of serious hypersensitivity reactions to rilpivirine, concurrent use of CYP3A4/5 inducers or inhibitors, use of other nonnucleoside reverse transcriptase inhibitors, lactation.
Use cautiously with prolonged QT interval, depressive disorders, pregnancy.
Available Forms
Tablets—25 mg
Dosages
Adults
25 mg/day PO with food. If also taking didanosine, didanosine should be taken at least 2 hr before or 4 hr after rilpivirine.
Pediatric patients
Safety and efficacy not established.
Pharmacokinetics
|
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
